Actualización del manejo del carcinoma ductal infiltrante luminal A en pacientes con enfermedad metastásica. Revisión Sistemática

Abstract

Background: Luminal invasive ductal carcinoma A presents HR to progesterone and estrogen, with the absence of HER2 and with the cell multiplication marker Ki67 below 14%. These particularities show a good prognosis, evolution, and prosperous response to hormone therapy (1,2). General Objective: To investigate the current management of patients with metastatic disease. Specific Objectives: To detail cyclin inhibitor drugs, to analyze safety considering response rate, overall survival, and side effects, and to compare efficacy and impact in relation to other therapies. Research Question: What is the management of luminal infiltrating ductal carcinoma A in patients with metastatic disease? Methods: Databases were analyzed to compile information, being SciELO, Scopus, and PubMed, considering observational, cost-effectiveness, randomized, descriptive, and meta-analysis studies of original articles on patients with advanced disease published locally and internationally, with a range of less than five years and available mainly in Spanish and English, in full text and open access. Results: Twenty-five scientific articles corresponding to the databases mentioned were analyzed; they were referenced with their title, author, year, objectives, the total sample size, and the results of these studies. Conclusions: The cyclin inhibitors Ribociclib, Palbociclib, and Abemaciclib, employed in the management of this neoplasm, are beneficial in terms of efficacy and tolerability; they present advantages by specifically targeting checkpoints in the cell period interfering with cancer cell proliferation. Keywords: carcinoma, breast, luminal A, metastasis, cyclin inhibitors